Speakers

Expand/Collapse

Eric Fedyk
Senior Vice President of Strategy
Relay Therapeutics

Day One

Tuesday June 22 2021

4:30 pm | The Potential of Repurposing BCMA-Targeted Biologics for Treating Autoimmune Diseases

Enrique Zudaire
Senior Scientific Director Head of Cell Therapy, Oncology Translational Research
Janssen Research & Development

Day Two

Wednesday June 23 2021

1:30 pm | Updated Correlative Analysis from CARTITUDE-1, a Phase 1b/2 Study of Cilta-cel, a BCMA-Targeted CAR-T Cell Therapy in Relapsed &/or Refractory Multiple Myeloma

9:00 am | Panel Discussion:: The Differentiating Debate: On-The-Shelf vs Off-The Shelf

David DiLillo
Director, Immuno- Oncology
Regeneron

Day Two

Wednesday June 23 2021

12:00 pm | Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumor Activity of CD3-Engaging Bispecific Antibodies

Hong Ma
Senior Vice President, Clinical Development
CARsgen Therapeutics

Mike Damore
Director & Lead - Translational Oncology
Pfizer

Day One

Tuesday June 22 2021

10:00 am | Panel Discussion: How Do Cell-Based vs Antibody-Based Anti-BCMA Therapies Compare?

Marc-Steffen Raab
Professor of Medicine
Heidelberg University

Day One

Tuesday June 22 2021

9:30 am | Advances in Antibody-Based Immunotherapy in Multiple Myeloma

Shambavi Richard
Associate Professor of Medicine (Hematology and Medical Oncology)
Mount Sinai Medical Center

Day One

Tuesday June 22 2021

9:00 am | Autologous BCMA Cell Therapies for the Treatment of Multiple Myeloma

10:00 am | Panel Discussion: How Do Cell-Based vs Antibody-Based Anti-BCMA Therapies Compare?

Shinta Cheng
Vice President Clinical Development
SpringWorks

Day Two

Wednesday June 23 2021

2:30 pm | Gamma Secretase Inhibitors: Potentiating BCMA-Targeted Therapies

Philip McCarthy
Director & Professor - Oncology & Internal Medicine, Transplant, Cellular Therapy Center & Medicine
Roswell Park Cancer Institute

Day One

Tuesday June 22 2021

1:30 pm | Toxicity to CAR-T Cell Therapy; When You’ve Seen One CAR-T Cell Patient You’ve Seen One CAR-T Cell Patient

Damian Green
Associate Professor - Clinical Research Division
Fred Hutchinson Cancer Research Center (FHCRC)

Day One

Tuesday June 22 2021

12:00 pm | Leveraging the Findings From First in-Human GSI-plus-BCMA Clinical Trial to Understand Mechanisms of Resistance & Optimize Efficacy

8:50 am | Chair’s Opening Remarks

Day Two

Wednesday June 23 2021

3:00 pm | Chair's Closing Remarks & End of Summit

8:50 am | Chair’s Opening Remarks

Christopher Heery
Chief Medical Officer
Arcellx

Day Two

Wednesday June 23 2021

11:30 am | ARC-sparX Platform Technology & Novel BCMA-Targeting Binding Domain for the Treatment of Patients with RRMM

Cesar Sommer
Senior Director
Allogene Therapeutics

Day One

Tuesday June 22 2021

3:30 pm | Allogeneic BCMA CAR-T Cell Therapy for the Treatment of Multiple Myeloma

Hans Chulhee Lee
Assistant Professor
MD Anderson Cancer Center

Day Two

Wednesday June 23 2021

9:00 am | Panel Discussion:: The Differentiating Debate: On-The-Shelf vs Off-The Shelf

Suzette Girgis
Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies
Johnson & Johnson Services

Day One

Tuesday June 22 2021

10:00 am | Panel Discussion: How Do Cell-Based vs Antibody-Based Anti-BCMA Therapies Compare?

Day Two

Wednesday June 23 2021

9:30 am | Teclistamab (BCMAxCD3) Journey from Discovery to Filing

Martina Sersch
Chief Medical Officer
Gracell Bio

Day One

Tuesday June 22 2021

4:00 pm | Disrupting Conventional Approaches to CAR-T Cell Therapies with our Proprietary Technology Platform—FasTCAR

Nathan Martin
Translational Scientist & Project Lead
Bristol Myers Squibb

Day Two

Wednesday June 23 2021

10:00 am | Correlates of Durable Response to Ide-Cel from the KarMMa Study

Nizar Bahlis
Associate Professor - Hematology & Oncology
University of Calgary

Dexiu Bu
Senior Principle Scientist, CART group, Immuno-Oncology & Hematology
Novartis Institute for Biomedical Research

Andreas Pahl
CSO & Executive Vice President
Heidelberg Pharma Research GmbH

Day One

Tuesday June 22 2021

2:00 pm | BCMA-ATAC: Updates on a Novel Mode of Action in Cancer Therapy

Brandon Kremer
Group Senior Medical Director, Clinical Development Lead
GlaxoSmithKline

Day Two

Wednesday June 23 2021

9:00 am | Panel Discussion:: The Differentiating Debate: On-The-Shelf vs Off-The Shelf

Chetasi Talati
Medical Director
AbbVie

Day Two

Wednesday June 23 2021

11:00 am | ABBV-383: A BCMA/CD3 Bispecific T-Cell Engager for the Treatment of Multiple Myeloma

9:00 am | Panel Discussion:: The Differentiating Debate: On-The-Shelf vs Off-The Shelf

Andrew Yee
Clinical Director & Assistant Professor of Medicine
Center for Multiple Myeloma, Harvard Medical School

Day One

Tuesday June 22 2021

11:30 am | Multiple Myeloma: A Clinical Perspective

Maria-Victoria Mateos
Consultant Physician, Myeloma Program & Clinical Trials Unit. Haematology Department & Associate Professor of Medicine
University of Salamanca

Day Two

Wednesday June 23 2021

2:00 pm | How to Select the Bi-Specific mAb For the Treatment of RRMM?

Frank Kuhr
Vice President, Medical Affairs North America
Menarini Silicon Biosystems

Day One

Tuesday June 22 2021

10:00 am | Panel Discussion: How Do Cell-Based vs Antibody-Based Anti-BCMA Therapies Compare?